TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04571827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell \& Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell \& Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell \& Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding.
Study: NCT03819010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib
Description: Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 18-25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib
Description: Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
Study: NCT03504514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: speech trials during different ventilation conditions
Description: ventilator parameters are modified

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speech trial
Description: reading duration, vocal flow, intelligibility and voice quality will be evaluated during speech
Study: NCT02749422

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MagStim RapidStim2
Description: Repetitive transcranial magnetic stimulation (TMS)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MagStim RapidStim2
Description: Repetitive transcranial magnetic stimulation (TMS)
Study: NCT00701207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
Study: NCT00538304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost eye drops
Description: 1 drop in each eye daily for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 drop in each eye daily for 1 month
Study: NCT01817855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7624
Description: Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match
Description: Multiple doses inhaled placebo via a nebulizer
Study: NCT00992511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: One intramuscular injection of initial process-manufactured GSK2340272A vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections of initial process-manufactured GSK2340272A vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: One intramuscular injection of new process-manufactured GSK2340272A vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections of new process-manufactured GSK2340272A vaccine
Study: NCT04276922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Arts
Description: Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance/Movement
Description: Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing/Poetry
Description: Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control Group will only complete surveys at baseline and 12 weeks later.
Study: NCT03260595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2%
Description: Crisaborole ointment 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study: NCT03910712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase inhibitor
Description: The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
Study: NCT01002456

Intervention type: OTHER
Group type: OTHER
Intervention: Level 1: (provide site-specifi information)
Description: provide site-specific information on non-adherence to guideline

Intervention type: OTHER
Group type: OTHER
Intervention: Level 2 (Provide site- and patient-specific information)
Description: provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
Study: NCT03491709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR monoclonal antibody
Description: Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab injection
Description: Cetuximab injection
Study: NCT04213924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl 0.5 % in 10 ml and 2 % lidocaine in 10 ml
Description: Erector spinae plane block, 30 min before the ESWL procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously
Description: 5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
Study: NCT03236051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Description: Multimodal analgesia is the name of a procedure or program. Multimodal analgesia doesn't mean different interventions are used. Patients in this group need receive this analgesia program (procedure) instead of one analgesic drug or technology. The program consists of incision infiltration with ropivacaine, intravenous injection of parecoxib, and oral administration of oxycodone/paracetamol mixture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCIA analgesia
Description: PCIA analgesia:patient-controlled intravenous analgesia with tramadol.
Study: NCT04058951

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Animal Protein Diet (HAPD)
Description: A diet containing 2,0 g protein per kilo body weight per day from primarily animal origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on beef isolate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Plant Protein Diet (HPPD)
Description: A diet containing 2,0 g protein per kilo body weight per day exclusively from plant origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on soy isolate.
Study: NCT05138523

Intervention type: COMBINATION_PRODUCT
Intervention: Sofosdac®
Description: Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir

Intervention type: COMBINATION_PRODUCT
Intervention: Sofosdac®
Description: Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir
Study: NCT00559442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude Exposure:
Description: rapid ascent to Margherita Hut (4559 m) within 24 h
Study: NCT00833911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once A Day
Study: NCT01399190

Intervention type: BIOLOGICAL
Intervention: Bevacizumab
Description: Bevacizumab administered according to prescribing information and normal clinical practice.

Intervention type: BIOLOGICAL
Intervention: Capecitabine
Description: Capecitabine administered according to prescribing information and normal clinical practice.

Intervention type: DRUG
Intervention: Oxaliplatin
Description: Capecitabine administered according to prescribing information and normal clinical practice.
Study: NCT00963833

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Patients under daily life treatment receiving Betaferon according to local product information.
Study: NCT00059839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given by mouth
Study: NCT04327804

Intervention type: DIAGNOSTIC_TEST
Intervention: Odd/Even birth year intervention groups
Description: The nostril used and order of testing will be different in each arm.

Intervention type: DIAGNOSTIC_TEST
Intervention: Odd/Even birth year intervention groups
Description: The nostril used and order of testing will be different in each arm.
Study: NCT04258800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music during colonoscopy
Description: Music during colonoscopy
Study: NCT00059839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV and intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV and intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT05873946

Intervention type: DIAGNOSTIC_TEST
Intervention: intraoperative ultrasound
Description: Use of 2D non-navigated intraoperative ultrasound as an operative adjunct
Study: NCT02709525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01693081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VR040/Aspirair® inhaler
Description: Dry Powder inhaled apomorphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04377828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pigment laser
Description: one to two session of pigment laser (532 nm)
Study: NCT01137955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 400mg orally three times a day for 10 days total

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally three times a day for 10 days total
Study: NCT01207596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Oral hydromorphone extended release, once daily
Study: NCT03150316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treat Regimen
Description: CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1\~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
Study: NCT01494454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System
Description: rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft/TSRH® or autograft/CD HORIZON® Spinal System.
Description: Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
Study: NCT01290705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High exercise therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low exercise therapy
Study: NCT01240083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thetaburst Stimulation
Description: Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency rTMS
Description: Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Stimulation
Description: Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
Study: NCT03953508

Intervention type: OTHER
Group type: OTHER
Intervention: Cigarette flavor type
Description: Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.

Intervention type: OTHER
Group type: OTHER
Intervention: Cigarette flavor type
Description: Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
Study: NCT00621894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-4665
Description: LGD-4665 Thrombopoietin mimetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00165633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menatetrenone
Description: 45 mg capsule, orally, three times a day, after meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menatetrenone
Description: 90 mg capsule, orally, three times a day, after meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, orally, three times a day, after meals.
Study: NCT01584154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: cryoablation with an 8mm-tip catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: radiofrequency ablation with a 4mm-tip catheter
Study: NCT02231125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abelmoschus manihot
Description: Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
Study: NCT04287842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac arrest
Description: Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac arrest
Description: Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac arrest
Description: Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
Study: NCT03678103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00029
Description: Noninvasive pulse oximeter sensor
Study: NCT00482924

Intervention type: OTHER
Intervention: Lifestyle intervention
Description: Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.